Coronavirus

A CDC report looked at 2 vaccine safety surveillance systems for the bivalent boosters in this population and there were no reports of myocarditis or death. Many of the reports were due to vaccine errors and not adverse events.

The two agencies said one of the vaccine surveillance systems prompted an investigation into whether there was a safety concern for ischemic stroke in seniors for this booster.

As COVID-19 continues to mutate, immunocompromised persons need new, effective treatments. Convalescent plasma could be the answer.

A randomized trial found the antidepressant to be ineffectual in helping improve time to sustained recovery.

A 2-year retrospective study looking at patients admitted to the ICU showed that the number of intubated males infected with Acinetobacter baumannii (AB) was double the number of intubated females.

Recent numbers show a lack of new people entering the field combined with existing shortfalls in many US locations.These factors demonstrate a potentially dangerous reduction in this vital medical specialty.

Research will focus on new technologies for early diagnosis of severe illnesses resulting from SARS-CoV-2 infection.

RSV cases spiked to unprecedented levels this season. Why were these infections so frequent and severe? Why has vaccine development taken so long?

Good news: across 23 countries, trust in COVID-19 vaccines increased 5.2% from 2021 to 2022. However, vaccine hesitancy remains in key populations.

The company is moving forward with vaccines to address respiratory and latent viruses as well as oncology.

Evusheld, the only FDA-approved COVID-19 pre-exposure prophylactic, is anticipated to be ineffective against the emerging XBB.1.5 variant.

The investigational antiviral showed the potential of another therapy that could benefit this patient population that is at risk for hospitalization and death.

“This was a total surprise,” said study lead author John Tsang, PhD.

In just a month, the XBB.1.5 variant went from causing 1% to over 40% of new COVID-19 infections.

Due to negative results, the I-SPY COVID Trial is no longer evaluating cyproheptadine to treat critically ill COVID-19 patients.

During the COVID-19 pandemic, cigarette sales differed from projected sales volume. One study examined these trends at the state level.

Sexually transmitted infections (STIs) received little attention during the pandemic, but the truth is the STIs did not stop infection increases shortly after the quarantine.

Although medical masks were noninferior to N95 in a multinational study of frontline health care workers, variability in circumstances between countries prevented researchers from drawing firm conclusions.

For providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.

New booster shots, antigen testing, and a shrinking incubation period: these were the top COVID-19 stories of 2022.

Vaccinations and mitigations for COVID-19 and other respiratory viruses have not been made a priority for young children. Let’s change this before the next big surge hits.

The new recommendation from the organization believes it will help avoid delays in patient care.

Virax Biolabs has developed a T-cell testing platform to develop an immune risk profile against viral threats.

Telemedicine use is likely to continue expanding even as the COVID-19 pandemic slowly resolves.

Roche’s Actemra is the first FDA approved monoclonal antibody to be used for COVID-19.

The committee will meet on January 26 to discuss whether and how the composition for primary doses of the currently available COVID-19 vaccines should be modified.

In a new CDC report, these immunizations aid against emergency department and urgent care encounters in immunocompetent adults.

2 years after the COVID-19 vaccine, we're focusing on who is still getting the most severe disease and why.

With these findings, the Uppsala University investigators believe loss of the Y chromosome in white blood cells can predict which patients are at high risk of severe COVID-19 disease progression.

A large health system saw a reduction of 40% and 70% respectively when the antiviral was prescribed.